Liquidmetal Technologies Inc splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $775,000, 99% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
| Product |
—
|
1
-8.0%
share 98.9%
|
1
+71.5%
share 97.9%
|
0
+36.0%
share 96.3%
|
0
-54.3%
share 94.3%
|
1
-14.6%
share 97.4%
|
1
share 93.5%
|
—
|
—
|
—
|
—
|
| License |
—
|
0
-50.0%
share 1.1%
|
0
-5.3%
share 2.1%
|
0
-13.6%
share 3.7%
|
0
+4.8%
share 5.7%
|
0
-67.2%
share 2.6%
|
0
share 6.5%
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Chemicals & Allied Products (SIC 2800)
- Listed as
- LQMT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lake Forest, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1141240
- Former names
- LIQUIDMETAL TECHNOLOGIES (until Nov 19, 2003)
Other Chemicals & Allied Products companies
- Akzo Nobel NV AKZOY
- Solstice Advanced Materials Inc. SOLS
- Balchem Corp BCPC
- Perimeter Solutions, Inc. PRM
- Ingevity Corp NGVT
- Innospec Inc. IOSP
- Chemours Co CC
- OLIN Corp OLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.